Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Last trade$5.59
Day change-$0.225 (-3.87%)
Day range$5.40 – $5.96
Volume18,909
Market cap$71M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$70.62M
Price / earnings
—
Price / book
13.25×
Price / sales
43.66×
EV / sales
41.64×
EV / EBITDA
-9.76×
Profitability
Earnings per share
-$0.57
Return on assets
-110.64%
Return on equity
-130.67%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
4.21×
Quick ratio
4.02×
Cash ratio
3.77×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.63M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NTRB, quarterly periods
Line item
Q2 FY2027 Jul 31, 2026
Q1 FY2027 Apr 30, 2026
Q4 FY2026 Jan 31, 2026
Q3 FY2026 Oct 31, 2025
Q2 FY2026 Jul 31, 2025
Q1 FY2026 Apr 30, 2025
Q4 FY2025 Jan 31, 2025
Q3 FY2025 Oct 31, 2024
Revenue
$437.51K
$433.4K
$400.71K
$346.06K
$622.45K
$667.43K
$642.38K
$645.8K
Cost of revenue
$255.64K
$236.6K
$311.77K
$277.55K
$465.57K
$415.45K
$356.44K
$454.77K
Gross profit
$181.87K
$196.8K
$88.94K
$68.51K
$156.88K
$251.98K
$285.94K
$191.03K
Selling, general and administrative
$750.32K
$1.2M
$921.82K
$3.49M
$1.6M
$982.05K
$1.76M
$737.1K
Research and development
$322.19K
$247.26K
$188.04K
$457.11K
$562.55K
$683.43K
$489.86K
$880.77K
Total operating expenses
$1.07M
$1.45M
$1.11M
$3.95M
$2.16M
$1.67M
$5.84M
$1.62M
Operating income
-$890.64K
-$1.25M
-$1.02M
-$3.88M
-$2M
-$1.41M
-$5.56M
-$1.43M
Interest expense
-$4.87K
-$5.01K
-$5.33K
-$5.55K
-$5.77K
-$5.88K
-$3.74K
-$4.03K
Income before taxes
-$880.56K
-$1.24M
-$968.06K
-$3.87M
-$2M
-$1.39M
-$5.52M
-$1.36M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$880.56K
-$1.24M
-$968.06K
-$3.87M
-$2M
-$1.39M
-$5.52M
-$1.36M
Net income attributable to common shareholders
-$880.56K
-$1.24M
-$968.06K
-$3.87M
-$23.81M
-$1.39M
-$5.52M
-$1.36M
EBITDA
-$857.31K
-$1.22M
-$985.04K
-$3.84M
-$1.95M
-$1.36M
-$1.89M
-$1.35M
Basic earnings per share
-$0.07
-$0.10
-$0.08
-$0.32
-$2.12
-$0.12
-$0.63
-$0.12
Diluted earnings per share
-$0.07
-$0.10
-$0.08
-$0.32
-$2.12
-$0.12
-$0.63
-$0.12
Recent news
Company coverage with links to the original publishers.
Nutriband Inc. received a USPTO Notice of Allowance for commercial brand name trademarks for its abuse-deterrent fentanyl transdermal patch incorporating AVERSA™ technology. The company is preparing preapproval regulatory submissions for the FDA, EMA, and international agencies, with peak annual U.S. sales potential estimated between $80-200 million.
Nutriband Inc. announced the appointment of former Navy SEAL Robert J. O'Neill to its Advisory Board. O'Neill, a decorated veteran and advocate for veterans' health, brings expertise in leadership and decision-making. His appointment supports Nutriband's advancement of AVERSA, an abuse-deterrent fentanyl patch candidate under development.
Nutriband Inc. announced key milestones from its January 2026 Annual Shareholders Meeting, including the addition of two new directors with strong financial and operational backgrounds. The company reported progress on its AVERSA™ abuse-deterrent fentanyl patch development, including patent grants, manufacturing scale-up completion, and FDA Type C meeting. However, the proposed sale of its Pocono Pharma subsidiary to EarthVision Bio remains incomplete, with the company collecting weekly penalty payments. Nutriband also filed a FINRA complaint regarding suspected naked short selling and reminded shareholders of warrant expiration in October 2026.
Nutriband Inc. reported significant progress in 2025 including the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5M with no shareholder dilution, a 25% preferred stock dividend, and major advances in its lead product AVERSA Fentanyl abuse-deterrent patch. The company received FDA Type C Meeting approval, completed manufacturing scale-up, secured additional patents, and was added to four Russell indexes. The CEO highlighted shareholder value focus and anticipated warrant expiration in October 2026 as a potential positive catalyst.
Nutriband Inc. announced the sale of a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million USD, with Nutriband shareholders retaining 10% ownership. The company plans to use proceeds to develop AVERSA Fentanyl, an abuse-deterrent opioid patch with potential annual US sales of $80-200 million. EarthVision Bio is developing sustainable product alternatives founded by Intel co-founder Dr. Gordon Moore and ex-Chevron Europe chairman Dr. Hans Franke.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.